Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: J Mol Cell Cardiol. 2020 May 1;143:120–131. doi: 10.1016/j.yjmcc.2020.04.032

Figure.9. Systemic administration of miRNA-27a* inhibitor partially improve heart contractility.

Figure.9

The experimental designs for the systemic delivery of miRNA-27a* inhibitor in CHF rats (A); qRT-PCR analysis of mature miRNA-27a* using specific TaqMan miRNA assay, U6 snRNA was used as an internal control (± SEM) (B); qRT-PCR analyses were performed with specific primers: PDLIM5 (C), BNP (D), ANP (E) and β-MHC (F), GAPDH was used as an internal control; Stroke volume (G and H) and cardiac output (I and J ) were analyzed by echocardiographic analyses (Mean ± S.E.M).